Cerebral Amyloid Angiopathy Limits Treatment of Stroke

Cerebral amyloid angiopathy (CAA) is a predominantly sporadic degenerative vasculopathy characterized by beta-amyloid deposition in the cerebral microvasculature, which may lead to lobar intracerebral and sulcal hemorrhage in older adults. Although relatively common after the 7th decade of life (>50% of persons), CAA rarely impacts the management of stroke in those living with CAA disease. In cases of severe CAA, reconsideration of traditional thrombolytic and antiplatelet therapies is warranted to reduce risk of CAA-related hemorrhage.